CerS2 ko in vivo reduces pro-inflammatory ceramides and improves doxorubicin mediated cardiotoxicity

Back

ESC Professional Premium Access

CerS2 ko in vivo reduces pro-inflammatory ceramides and improves doxorubicin mediated cardiotoxicity

Session: Cardiotoxicity of drugs and other therapies

Topic: Cardiotoxicity of Drugs and Other Therapies

Speaker: Doctor T. Kretzschmar (Jena, DE)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Tom Kretzschmar

University hospital Jena, Jena (Germany)

0 follower

6 more presentations in this session

Pre-diabetes is associated with increased cardiac events in cancer patients prescribed anthracyclines

Speaker: Doctor I. Cheang (Nanjing, CN)

Prognostic value of 6-minute walking test for early prediction of doxorubicin induced cardiotoxicity

Speaker: Mrs G. Muckiene (Kaunas, LT)

Usefulness of the baseline risk assessment guidelines to predict cancer therapy-related cardiac dysfunction in early-stage HER2 positive breast cancer

Speaker: Doctor G. Oristrell Santamaria (Barcelona, ES)

Initial phase of anthracycline cardiotoxicity involves metabolic switch and activation of cardiac fibroblasts

Speaker: Associate Professor K. Urbanek (Naples, IT)

Effect of vitamin D receptor genetic polymorphism on the clinical response to angiotensin converting enzyme inhibitors therapy among breast cancer patients with chemotherapy induced cardiomyopathy

Speaker: Miss I. Al-Ansary (Cairo, EG)

Access the full session

Cardiotoxicity of drugs and other therapies

Speakers: Doctor T. Kretzschmar, Doctor I. Cheang, Mrs G. Muckiene, Doctor G. Oristrell Santamaria, Associate Professor K. Urbanek...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources